CD3-HM30L | 价格

CD3-HM30L-100μg / 询价

CD3-HM30L-500μg / 询价

CD3-HM30L-500μgx2 / 询价

Human CD30 Ligand/TNFSF8 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human CD30 Ligand/TNFSF8 Protein is expressed from HEK293 with mFc (IgG2a) tag at the N-Terminus.
It contains Gln63-Asp234 [Accession | P32971-1].

分子量大小(Molecular Weight)

The protein has a predicted MW of 46.2 kDa. Due to glycosylation, the protein migrates to 62-68 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human CD30 Ligand on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Human CD30 Ligand is greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized Human CD30, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Human CD30 Ligand, mFc Tag with the EC50 of 10.5ng/ml determined by ELISA.

背景(Background)

CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells.CD30L is a cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells.

分子别名(Synonyms)

CD153; CD30 Ligand; CD30L; CD30-L; CD30LGMGC138144; TNFSF8; CD30LG

文献(References)

(1)Van d W C A , Pileri S A , Feldman A L , et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions[J]. Blood Cancer Journal, 2017, 7(9):e603.

Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.